BioXcel Therapeutics (BTAI) Cash from Investing Activities (2018 - 2022)
BioXcel Therapeutics (BTAI) posted quarterly Cash from Investing Activities of -$19000.0 for Q2 2022, up 81.0% year-over-year from -$10497.2 in Q2 2021, and up 84.17% quarter-over-quarter from -$120000.0 in Q1 2022.
BioXcel Therapeutics (BTAI) Cash from Investing Activities (2018 - 2022) Analysis & Trends
BioXcel Therapeutics' Cash from Investing Activities history runs 5 years deep, the most recent figure standing at -$19000.0 for Q2 2022.
- In Q2 2022, Cash from Investing Activities rose 81.0% year-over-year to -$19000.0; the TTM figure through Sep 2023 stood at -$19000.0 (up 87.42% YoY), while the FY2023 annual figure was -$20000.0, up 85.61% from the prior year.
- Cash from Investing Activities for Q2 2022 stood at -$19000.0, up from -$120000.0 in the prior quarter.
- The five-year high for Cash from Investing Activities was $5000.0 in Q3 2020, with the low at -$600000.0 in Q1 2019.
- The 5-year median for Cash from Investing Activities is -$52500.0 (2018), against an average of -$124375.0.
- Peak annual rise in Cash from Investing Activities reached 111.63% in 2020, while the deepest fall reached 13400.0% in 2020.
- BioXcel Therapeutics' Cash from Investing Activities stood at -$158000.0 in 2018, then jumped by 98.73% to -$2000.0 in 2019, then sank by 13400.0% to -$270000.0 in 2020, then jumped by 95.56% to -$12000.0 in 2021, then tumbled by 58.33% to -$19000.0 in 2022.
- Business Quant data shows BTAI's Cash from Investing Activities at -$19000.0 in Q2 2022, -$120000.0 in Q1 2022, and -$12000.0 in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -491.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | -300.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -550.24 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 87.50 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -51.60 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | -135.40 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | -110.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | BioXcel Therapeutics | 24.25 Mn | 24.25 Mn | 160,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2022 | -19,000.00 |
| Jun 30, 2022 | -19,000.00 |
| Mar 31, 2022 | -120,000.00 |
| Mar 31, 2022 | -120,000.00 |
| Dec 31, 2021 | -12,000.00 |
| Dec 31, 2021 | -12,000.00 |
| Sep 30, 2021 | -17,000.00 |
| Sep 30, 2021 | -17,000.00 |
| Jun 30, 2021 | -100,000.00 |
| Jun 30, 2021 | -100,000.00 |
| Mar 31, 2021 | -316,000.00 |
| Mar 31, 2021 | -316,000.00 |
| Dec 31, 2020 | -270,000.00 |
| Dec 31, 2020 | -270,000.00 |
| Sep 30, 2020 | 5,000.00 |
| Sep 30, 2020 | 5,000.00 |
| Jun 30, 2020 | -35,000.00 |
| Jun 30, 2020 | -35,000.00 |
| Mar 31, 2020 | -16,000.00 |
| Mar 31, 2020 | -16,000.00 |